Spruce Point Capital Management · activist-deck
Penumbra, Inc. (PEN)
61 pages · 3 arc beats · 2 loops
Penumbra, Inc. (PEN)
Spruce Point Capital Management · 2019-07 arc beats above · slides in the middle · loops below · scroll → 2 LOOPS
15101520253035404550556061
Deck intelligence map
3 coverage by narrative range · generated from this deck JSON
Narrative range 61 total
Metadata
Components
Metrics
Tools
Frameworks
Beats
Loops
The Monster 10 slides 100% 10/10 slides 100% 10/10 slides · 58 hits — 0/10 slides
50% 5/10 slides 50% 5/10 slides 100% 10/10 slides 40% 4/10 slides The Struggle 20 slides 100% 20/20 slides 100% 20/20 slides · 116 hits — 0/20 slides
15% 3/20 slides 45% 9/20 slides 100% 20/20 slides — 0/20 slides
The Victory 31 slides 100% 31/31 slides 100% 31/31 slides · 211 hits — 0/31 slides
— 0/31 slides
71% 22/31 slides 100% 31/31 slides 12.9% 4/31 slides Slide inventory
61 every slide · same image gating as the playbook
01
The image uses a medical surgery metaphor to imply the company is in critical condition or being 'operated' on by the short seller. A rat is visible on the medifront_matter
Open slide detailBeat · The Monster
03
The slide uses a comparison table to establish credibility by highlighting past successful short-selling campaigns.cite_precedent
Open slide detailBeat · The Monster
05
The slide uses a dense, text-heavy format typical of activist short reports to establish the core investment thesis.frame_problem
Open slide detailBeat · The Monster
06
The slide emphasizes the proprietary/exclusive nature of the data to build credibility for the activist's thesis.analyze_data
Open slide detailBeat · The Monster
07
Uses red dashed lines to visually connect the decline in sales to the negative growth metrics and the contrast with the growing market.expose_contradiction
08
The slide uses a table to correlate Penumbra's YoY growth decline with the emergence of Medtronic's React 68 and React 71 products.expose_contradiction
09
The slide uses red boxes to highlight the decline in Penumbra's market share.expose_contradiction
10
The table models a 'race to the bottom' pricing strategy for Medtronic's aspiration products to gain market share.analyze_data
11
Includes hand-drawn red annotations on the left chart highlighting a discrepancy in the TAM.expose_contradiction
Open slide detailBeat · The Struggle
12
The table highlights the discrepancy between market consensus and the activist's bearish outlook, specifically using red boxes to emphasize the lower revenue ancompare_peers
Open slide detailBeat · The Struggle
13
The slide highlights a contradiction between the company's regulatory pathway (510(k)) and its valuation relative to PMA-cleared peers.compare_peers
Open slide detailBeat · The Struggle
14
Includes adjustments for lease payments, contingent consideration, minority interest, and cash/debt.analyze_data
Open slide detailBeat · The Struggle
16
Includes medical illustrations of a brain clot and a leg vein clot.establish_context
Open slide detailBeat · The Struggle
17
Includes a visual process flow for stent retrieval and a description of the 'Solumbra' combined technique.establish_context
Open slide detailBeat · The Struggle
18
Includes a screenshot of the NEJM article header and a data table from the supplementary appendix.cite_precedent
Open slide detailBeat · The Struggle
19
The slide uses a grid layout to present four distinct clinical study summaries, each with a title, article reference, and conclusion.cite_precedent
Open slide detailBeat · The Struggle
20
The table uses red and green borders to highlight negative vs positive outcomes/trial status.cite_precedent
Open slide detailBeat · The Struggle
21
The slide argues that Solumbra is the fastest-growing technique, implying a competitive advantage for vendors offering both aspiration and stent retriever technsize_opportunity
Open slide detailBeat · The Struggle
22
The slide uses a table to demonstrate the timeline of FDA approvals for competitors, contrasting them with Penumbra's 2007 entry.preempt_rebuttal
Open slide detailBeat · The Struggle
23
Spruce Point Capital Management branding (pine tree logo).transition
Open slide detailBeat · The Struggle
24
The slide uses two tables to show implied market share by procedure count and dollar value, highlighting the decline in share over time as a point of skepticismpreempt_rebuttal
Open slide detailBeat · The Struggle
25
The slide uses two bar charts to illustrate the 'unsophisticated' nature of sell-side projections for patient volume and market share.expose_contradiction
Open slide detailBeat · The Struggle
26
Uses a call-and-response format to present evidence of a market share discrepancy.expose_contradiction
Open slide detailBeat · The Struggle
27
The slide uses two 100% stacked bar charts to visualize the contradiction between analyst estimates and company claims.expose_contradiction
Open slide detailBeat · The Struggle
28
The slide emphasizes the proprietary and exclusive nature of the data to bolster the credibility of the activist's analysis.analyze_data
Open slide detailBeat · The Struggle
29
Uses red boxes and arrows to highlight negative trends in contrast to the overall market growth.expose_contradiction
Open slide detailBeat · The Struggle
30
The slide uses a table to show the inverse relationship between Penumbra's growth and Medtronic's market entry, with a callout box explaining why the Medtronic expose_contradiction
Open slide detailBeat · The Struggle
31
Includes red box annotations highlighting the convergence of delta and growth trends.analyze_data
Open slide detailBeat · The Victory
32
The slide uses primary research (interviews) to corroborate quantitative market share loss.expose_gap
Open slide detailBeat · The Victory
33
The chart uses a dual-axis combination (bar and line) to correlate revenue guidance raises with quarterly revenue beats.expose_contradiction
35
The slide uses a 'villain critique' approach to frame the company as a one-product firm with a vulnerable moat.name_villain
36
The slide uses a series of testimonials from neurosurgeons to undermine the 'bull case' that Penumbra's market share is secure.expose_contradiction
37
Highlights FDA approval documents for Medtronic React 68 and Stryker AXS Catalyst to show direct comparison to Penumbra's predicate devices.expose_gap
Open slide detailBeat · The Victory
38
The slide uses testimonials to frame a competitive disadvantage for the subject company (Penumbra) regarding pricing power and bundling capabilities.expose_contradiction
Open slide detailBeat · The Victory
39
The table models five scenarios for Medtronic's aspiration pricing ($4k down to $0) and calculates the resulting financial impact.analyze_data
Open slide detailBeat · The Victory
40
Uses direct quotes to establish a 'villain' narrative regarding product quality.name_villain
Open slide detailBeat · The Victory
41
The slide uses a stacked bar chart to show market growth and a grouped bar chart to compare market share estimates between sell-side and Spruce Point.expose_contradiction
Open slide detailBeat · The Victory
42
The chart highlights a divergence in growth expectations between the market consensus and the activist's thesis.expose_gap
Open slide detailBeat · The Victory
43
Spruce Point Capital Management branding (tree logo).transition
Open slide detailBeat · The Victory
44
Uses testimonials from neurosurgeons and a sales director to undermine management's credibility.expose_contradiction
Open slide detailBeat · The Victory
45
The slide highlights a red-bordered row for Penumbra, Inc. to emphasize the anomaly.expose_contradiction
Open slide detailBeat · The Victory
46
Uses testimonials from industry participants to support the claim of aggressive marketing tactics.expose_contradiction
Open slide detailBeat · The Victory
47
Includes a quote from a Neurovascular Products Sales Director to reinforce the point.expose_contradiction
Open slide detailBeat · The Victory
48
The chart shows a clear upward trend in DSO from Q3-2016 to Q1-2019, supporting the thesis of artificial inflation.expose_contradiction
Open slide detailBeat · The Victory
49
Uses screenshots of LinkedIn and a clinical study abstract to undermine management's strategic decision-making.name_villain
Open slide detailBeat · The Victory
50
Uses red arrows to highlight the correlation between the acquisition timing and financial metrics.expose_contradiction
Open slide detailBeat · The Victory
51
The slide uses a table to establish a pattern of behavior (distributor acquisitions) as a predictive indicator of corporate failure.cite_precedent
Open slide detailBeat · The Victory
52
The slide uses testimonials from medical professionals to frame the company's regulatory actions as anti-competitive 'bully tactics'.expose_contradiction
Open slide detailBeat · The Victory
53
Includes a red hand-drawn annotation on the left chart highlighting the exclusion of 'Vascular Access' from the TAM.expose_contradiction
Open slide detailBeat · The Victory
54
The slide uses a grouped bar chart to visualize the gap between market consensus and the activist's thesis.compare_peers
Open slide detailBeat · The Victory
56
The table uses red boxes to highlight the Spruce Point estimates that differ from the sell-side consensus.expose_gap
Open slide detailBeat · The Victory
57
The slide highlights Penumbra's valuation relative to its peers, specifically contrasting PMA vs 510(k) pathways.compare_peers
Open slide detailBeat · The Victory
58
The table segments peers by FDA pathway (PMA vs 510K) to highlight that PEN is trading at multiples inconsistent with its lower-tier 510K status and weaker fundcompare_peers
Open slide detailBeat · The Victory
59
The slide uses a Bloomberg terminal screenshot to provide 'objective' market data to support the activist thesis of insider dumping.expose_contradiction
Open slide detailBeat · The Victory
60
The slide uses a table to demonstrate that despite 'Buy' ratings, the average price target implies negative upside.expose_contradiction
Open slide detailBeat · The Victory
61
The table explicitly calculates the percentage change from current sell-side estimates to the activist's bear/bull cases across key financial metrics.show_valuation_bridge
Open slide detailBeat · The Victory